Peripheral CD8 + PD-1 + T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer

Author:

Guo Wenwen1,Qiao Tianyun1,Li Hui1,Zhao Yong1,Qin Jing1,Zhang Caiqin1,Shi Changhong1

Affiliation:

1. Air Force Medical University

Abstract

AbstractBackground Neoadjuvant immunotherapy has shown promising clinical activity in the treatment of early non-small cell lung cancer (NSCLC); however, further clarification of the specific mechanism and identification of biomarkers are imperative prior to implementing it as a daily practice. Methods We investigated the impact of neoadjuvant chemoimmunotherapy (combining cisplatin with pembrolizumab) on an established preclinical NSCLC mouse model engrafted with human immune system, and explored its potential mechanism. We further explored potential biomarkers for neoadjuvant therapy and conductedin vivovalidation using the model. In addition, both peripheral blood and tumor specimens from 14 patients undergoing neoadjuvant chemoimmunotherapy were analyzed to validate our findings. Results Neoadjuvant chemoimmunotherapy could prevent postoperative recurrence and metastasis by increasing the frequency and activation of CD8+T cells in both peripheral blood and tumor immune microenvironment (TIME). The kinetics of peripheral CD8+PD-1+T cells reflected the changes in the TIME and pathological responses, ultimately predicting survival outcome of mice. Further analysis of clinical specimens not only confirmed the reprogramming of TIME, but also validated CD8+PD-1+T cells as rational biomarker. Conclusions The kinetics of peripheral CD8+T cells can serve as a predictor for changes in TIME and overall antitumor immune responses, ultimately reflecting the outcomes of neoadjuvant chemoimmunotherapy in both preclinical and clinical setting. Our findings establish a theoretical foundation for the clinical translation of this promising biomarker.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3